Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection (AntiCov-220)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05043324
Recruitment Status : Active, not recruiting
First Posted : September 14, 2021
Last Update Posted : September 24, 2021
Sponsor:
Information provided by (Responsible Party):
Nguyen Thi Trieu, MD, Trieu, Nguyen Thi, M.D.

Brief Summary:
AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Condition or disease Intervention/treatment Phase
Covid19 Drug: AntiCov-220 Phase 2

Detailed Description:

AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body.

AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before.

AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ...

The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation.

AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations.

AntiCov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health.

AntiCov-220 can be used alongside with current standard treatment regimens prescribed by the World Health Organization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
Actual Study Start Date : February 20, 2020
Estimated Primary Completion Date : February 20, 2022
Estimated Study Completion Date : February 27, 2022

Arm Intervention/treatment
Experimental: AIDS, HIV, HBV, HCV, co-infections.
Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes.
Drug: AntiCov-220
The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.

Experimental: "stable" cancer, acquired or congenital immunodeficiency.
Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 for various therapeutic purposes.
Drug: AntiCov-220
The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.




Primary Outcome Measures :
  1. Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1) [ Time Frame: - 18 months ]

    COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19

    • One case of Covid-19 infection with no severe change in a patient with HBeAg (+).
    • A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated).


Secondary Outcome Measures :
  1. Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2) [ Time Frame: - 18 months ]

    COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19

    _ No one has been infected with Covid-19. Of the 47 follow-up subjects in this group, 40 were vaccinated and 7 were unvaccinated.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 82 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All patients with underlying medical conditions who have been taking medications for these conditions.
  • Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
  • The cancer patients are stable.
  • Patients with congenital or acquired immunodeficiency.

Exclusion Criteria:

  • Unstable cancer patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05043324


Locations
Layout table for location information
Vietnam
Saigon Biopharma Company Limited
Ho Chi Minh City, Vietnam, 700000
Sponsors and Collaborators
Nguyen Thi Trieu, MD
Investigators
Layout table for investigator information
Principal Investigator: Tran Minh Cam Tu, Dr. Saigon Biopharma Company Limited
Additional Information:
Publications of Results:
Natural Products Structural Diversity-I Secondary Metabolites: Organization and Biosynthesis
Herbal Support for Adrenal Function BY JAMES ROUSE, N.D.
Clinical characteristics, multi-organ dysfunction, and outcomes of patients with COVID-19: A prospective observational study
Vitamin C (Ascorbic Acid) Muhammad Abdullah; Radia T. Jamil; Fibi N. Attia.

Layout table for additonal information
Responsible Party: Nguyen Thi Trieu, MD, CEO, Trieu, Nguyen Thi, M.D.
ClinicalTrials.gov Identifier: NCT05043324    
Other Study ID Numbers: COVID-19 and Immunodeficiency
First Posted: September 14, 2021    Key Record Dates
Last Update Posted: September 24, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nguyen Thi Trieu, MD, Trieu, Nguyen Thi, M.D.:
AIDS
HIV
HBV
HCV
Stroke
Metabolic dissorder
Stress
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Infections
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases